Sponsored by Epstein Becker & Green, P.C.
MedTech Metro is an intimate forum and networking series designed to showcase New York’s bioscience and medical technology (Bio/Med) before an audience of investors, business leaders, and health care providers, and other service professionals committed to promoting and supporting the Bio/Med industry.
MedTech is the hub of New York State’s bioscience and medical technology industry. It is an active association of nearly 100 pharmaceutical, biotech, and medical technology companies, their suppliers and service providers and research universities.
LaunchNY, Marnie LaVigne, Ph.D., President and CEO
Dr. LaVigne is one of the most recognizable faces in economic development in New York State. Formerly Associate Vice President of Economic Development at the University at Buffalo, she joined LaunchNY in July to lead organizational efforts to support and invest in high-growth business ventures and catalyze the entrepreneurial culture of upstate New York.
Dr. LaVigne will discuss her new focus for expanding LaunchNY’s influence, as well as efforts underway, including 43North, “the world’s largest business idea competition” with $5 million in cash prizes scheduled October 24 – 30 in Buffalo, New York.
CPSI Biotech is a private, integrative medtech greenhouse company that has recently developed the FrostBite™ cryoablation technology platform for the minimally invasive in situ treatment of gastroenterological diseases, including pancreatic, esophageal, and colorectal cancers. The system delivers an ultra-cold fluid from the cryogenic console through a disposable endoscopic ultrasound compatible cryocatheter to freeze tissue in place within the body. The patent-pending FrostBite™ platform has been tested in a series of engineering, in vitro, and pre-clinical pilot studies, in conjunction with our clinical partners at Johns Hopkins School of Medicine, and has shown to provide for a highly effective next-generation cancer ablation treatment path.
CPSI Biotech is seeking to raise $3-5 million in funding to support FrostBite™ platform finalization, regulatory approval, and commercial launch within the next 14-18 months.
Angulus, LLC, is positioned to solve the problem of ventilator-associated pneumonia (VAP), a cause of morbidity and mortality across ICU units. Guidelines recommend that ventilated patients be positioned at 30 to 45 degrees to reduce the risk of VAP, but compliance among providers remains poor. Furthermore, patients often slide down hospital beds, mitigating the benefit of head of bed angle compliance. Based on intellectual property owned by the company, Angulus is the only device that attaches to a patient’s chest wall, evaluates real-time patient angle, and integrates with existing ICU systems to signal providers when patients slide outside the desired recumbency.
Angulus is currently preparing for initial pilot studies to assess the use of the device in the clinical setting in late 2014 or early 2015. The company is seeking hospital and product partners that will lead to additional sites for testing. The company is funded through April 2015, but is starting to ramp up efforts for a seed round of $1 million.
PurpleSun, Inc. is a fast growing early-stage infection control company that takes a novel approach to UVC light technology for the decontamination of patients’ rooms, operating theaters, and complex medical equipment. Federal and state laws, as well as the scientific and clinical communities, are currently driving hospitals to adopt these new products and technologies. The validation study completed on the first generation models by the Walsh Lab demonstrates unmatched rapid killing performance of multi-drug resistant organisms, such as MRSA (15 seconds) and C.difficile (60 seconds). PurpleSun aims to become the new standard technology used by health care facilities to prevent infections and provide safer patient environments.
|5:00-5:30 p.m.||Registration / Cocktail and Networking Reception|
|5:30-5:45 p.m.||Welcome by Jessica Crawford, President, MedTech Association|
Introduction by Bethany Hills, Member, Epstein Becker & Green
|5:45-6:45 p.m.||Presentations by:|
John M. Baust, Ph.D., President and Founder, CPSI Biotech
Frank Glaser, Founder and CEO, Angulus Device
Luis Romo, President and CEO, PurpleSun
|6:45-7:30 p.m.||Marnie LaVigne, President and CEO, LaunchNY|
To RSVP, please click here.
If you have questions about this briefing, please contact Whitney Krebs at (202) 861-1845 or firstname.lastname@example.org.